FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096731434> ?p ?o ?g. }

• W3096731434 endingPage "25" @default.
• W3096731434 startingPage "24" @default.
• W3096731434 abstract "Background: Targeted inhibition of the FLT3 tyrosine kinase is a treatment strategy for patients with relapsed or refractory, FLT3 mutation-positive acute myeloid leukemia (R/R FLT3mut+ AML). While the multikinase inhibitors, sorafenib and midostaurin, were not approved specifically for R/R AML, they are used off-label as treatment. Since FDA approval on 11/28/2018, gilteritinib has become the first globally approved targeted therapy for the treatment of R/R FLT3mut+ AML in adults. This study aims to understand the treatment landscape for R/R FLT3mut+ AML patients following the introduction of a new therapeutic agent. Aim/Objective: To describe the characteristics and treatment patterns of patients initiating FLT3 tyrosine kinase inhibitors (TKIs) for R/R FLT3mut+ AML in the real-world setting. Methods: This US-based retrospective cohort study was conducted using two separate closed-claims databases (MarketScan, 1/1/2007-2/29/2020; IQVIA, 1/1/2006-4/30/2020) and a specialty-pharmacy claims database (ProMetrics, 12/6/2018-3/12/2020). Patients ≥18 years of age, with an AML diagnosis and newly initiated FLT3-TKI (ie, gilteritinib, midostaurin, or sorafenib) therapy for R/R diagnosis or episode (R/R AML) on or after gilteritinib market availability were eligible for inclusion. Patients were indexed on the first newly initiated FLT3-TKI for R/R AML observed on or after 12/1/2018. Patients' baseline clinical and demographic characteristics, AML-related treatments preceding FLT3-TKI initiation for R/R AML, and concomitant therapies (defined as any AML-related treatment overlapping with FLT3-TKI use after R/R AML) were identified. Because individual patients could have received more than one FLT3-TKI during the study period, treatment sequencing was analyzed by FLT3-TKI-containing regimens. Given the larger sample size available within the ProMetrics Specialty Pharmacy database, gilteritinib dose patterns and treatment duration were analyzed using de-identified dispensed prescription data from a separate gilteritinib-only cohort for greater precision. Descriptive statistics were used to evaluate all study outcomes, except for treatment duration, which was estimated using Kaplan-Meier life table analysis. Results: A total of 52 and 51 patients initiating FLT3-TKIs for R/R AML were identified in the MarketScan and IQVIA databases, respectively. The mean age of patients was 53.1 (MarketScan) and 52.3 years (IQVIA); patients had a mean ± SD Quan-Charlson Comorbidity Index of 3.6 ± 2.4 (MarketScan) and 3.7 ± 2.2 (IQVIA). Most patients treated with FLT3-TKIs for R/R AML during the study period were first initiated on gilteritinib (MarketScan: n=35 [67.3%], IQVIA: n=36 [70.6%]); sorafenib was the second most common FLT3-TKI (MarketScan: n=9 [17.3%], IQVIA: n=8 [15.7%]), followed by midostaurin (MarketScan: n=8 [15.4%], IQVIA: n=7 [13.7%]). During the study period, 61 and 55 FLT3-TKI-containing regimens among 52 and 51 R/R AML patients were identified across the MarketScan and IQVIA databases, respectively. Most FLT3-TKI-containing regimens for R/R AML included gilteritinib (MarketScan: n=43 [70.5%], IQVIA: n=38 [69.1%]). Prior exposure to other FLT3-TKIs for new onset and/or R/R AML indications was observed in up to 63% of gilteritinib-, 56% of sorafenib-, and 13% of midostaurin-containing regimens (Table). Following onset of R/R AML, gilteritinib was given without concomitant chemotherapy in 47% (Marketscan: 20/43) to 55% (IQVIA: 21/38) of gilteritinib regimens; in a smaller sample of sorafenib regimens, sorafenib was given without concomitant chemotherapy in up to 56% (IQVIA: 5/9) of regimens. Of 748 patients identified in the ProMetrics database with gilteritinib claims, 714 (95%) patients were initiated on a 120-mg daily dose, with less than 5% (n=34) incurring a downward dosage titration. The median treatment duration was 150 days (95% CI: 129-172 days). Conclusions: Among FLT3-TKI-containing regimens initiated for R/R AML after gilteritinib market approval, close to 70% included gilteritinib, an agent approved for R/R FLT3mut+ AML. Sample sizes for midostaurin- and sorafenib-containing regimens limited characterization of treatment patterns. Gilteritinib was given without concomitant chemotherapy in approximately 50% of regimens prescribed; the dose and treatment durations were similar to those previously reported by the ADMIRAL trial. Disclosures Grinblatt: Astellas: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Alexion: Speakers Bureau. Pandya:Astellas Pharma, Inc.: Current Employment. Sullivan:Astellas Pharma: Current Employment. Feng:Astellas: Current Employment. Hedlund:Astellas: Current Employment." @default.
• W3096731434 created "2020-11-09" @default.
• W3096731434 creator A5007821162 @default.
• W3096731434 creator A5020140533 @default.
• W3096731434 creator A5022506401 @default.
• W3096731434 creator A5042347385 @default.
• W3096731434 creator A5061445062 @default.
• W3096731434 creator A5083966671 @default.
• W3096731434 date "2020-11-05" @default.
• W3096731434 modified "2023-09-27" @default.
• W3096731434 title "Real-World Use of FLT3-TKIs in R/R FLT3-Mutated AML in the United States" @default.
• W3096731434 doi "https://doi.org/10.1182/blood-2020-136391" @default.
• W3096731434 hasPublicationYear "2020" @default.
• W3096731434 type Work @default.
• W3096731434 sameAs 3096731434 @default.
• W3096731434 citedByCount "1" @default.
• W3096731434 countsByYear W30967314342023 @default.
• W3096731434 crossrefType "journal-article" @default.
• W3096731434 hasAuthorship W3096731434A5007821162 @default.
• W3096731434 hasAuthorship W3096731434A5020140533 @default.
• W3096731434 hasAuthorship W3096731434A5022506401 @default.
• W3096731434 hasAuthorship W3096731434A5042347385 @default.
• W3096731434 hasAuthorship W3096731434A5061445062 @default.
• W3096731434 hasAuthorship W3096731434A5083966671 @default.
• W3096731434 hasConcept C126322002 @default.
• W3096731434 hasConcept C143998085 @default.
• W3096731434 hasConcept C2776481607 @default.
• W3096731434 hasConcept C2778019345 @default.
• W3096731434 hasConcept C2778695046 @default.
• W3096731434 hasConcept C2778729363 @default.
• W3096731434 hasConcept C71924100 @default.
• W3096731434 hasConceptScore W3096731434C126322002 @default.
• W3096731434 hasConceptScore W3096731434C143998085 @default.
• W3096731434 hasConceptScore W3096731434C2776481607 @default.
• W3096731434 hasConceptScore W3096731434C2778019345 @default.
• W3096731434 hasConceptScore W3096731434C2778695046 @default.
• W3096731434 hasConceptScore W3096731434C2778729363 @default.
• W3096731434 hasConceptScore W3096731434C71924100 @default.
• W3096731434 hasIssue "Supplement 1" @default.
• W3096731434 hasLocation W30967314341 @default.
• W3096731434 hasOpenAccess W3096731434 @default.
• W3096731434 hasPrimaryLocation W30967314341 @default.
• W3096731434 hasRelatedWork W1234653855 @default.
• W3096731434 hasRelatedWork W1973417574 @default.
• W3096731434 hasRelatedWork W2562399451 @default.
• W3096731434 hasRelatedWork W2894770453 @default.
• W3096731434 hasRelatedWork W2902063722 @default.
• W3096731434 hasRelatedWork W2913286502 @default.
• W3096731434 hasRelatedWork W2943918881 @default.
• W3096731434 hasRelatedWork W3201095442 @default.
• W3096731434 hasRelatedWork W4229374919 @default.
• W3096731434 hasRelatedWork W4280536749 @default.
• W3096731434 hasVolume "136" @default.
• W3096731434 isParatext "false" @default.
• W3096731434 isRetracted "false" @default.
• W3096731434 magId "3096731434" @default.
• W3096731434 workType "article" @default.